Core Insights - Humacyte, Inc. has received Electronic Catalog (ECAT) listing approval for its product Symvess, making it accessible to healthcare professionals in U.S. Department of Defense and Department of Veterans Affairs facilities [1] - Symvess is an acellular tissue engineered vessel that was approved by the FDA for extremity vascular trauma in December 2024 [2] - The company aims to expand the availability of Symvess to more patients, having received positive feedback from DOD hospitals [3] Company Overview - Humacyte, Inc. is focused on developing bioengineered human tissues and advanced tissue constructs to improve patient care and transform medical practices [4] - The company’s acellular tissue engineered vessel (ATEV) has received FDA approval for vascular trauma and is in late-stage clinical trials for other vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease [4] - Humacyte's 6mm ATEV has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA, indicating its potential for urgent arterial repair and advanced PAD treatment [4]